Julie C. Martin

Dr. Julie C. Martin

Cancer Institute, Prisma Health, Greenville, Alabama, USA
orcid

Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 May 2013 in Cancer Chemotherapy and Pharmacology
Verified
Journal Article
Closed access
PDF file
ATAntoinette R. Tan
Antoinette R. Tan
DGDarlene G. Gibbon
Darlene G. Gibbon
MSMark N. Stein
Mark N. Stein
DLDiana Lindquist
Diana Lindquist
JEJeffery W. Edenfield
Jeffery W. Edenfield
JSJoseph J. Stephenson
Joseph J. Stephenson

1 February 2014 in Lung Cancer
Verified
Journal Article
Closed access
JSJoe J. Stephenson
Joe J. Stephenson
JNJohn Nemunaitis
John Nemunaitis
AJAnil A. Joy
Anil A. Joy
Julie C. MartinJulie C. Martin
Julie C. Martin
YJYing-Ming Jou
Ying-Ming Jou
MEMartin J. Edelman
Martin J. Edelman

26 September 2021 in Cancers
Verified
Journal Article
Open access
PDF file
BBBailey Blair
Bailey Blair
AFAvery T. Funkhouser
Avery T. Funkhouser
JGJane L. Goodwin
Jane L. Goodwin
ASAlexander Strigenz
Alexander Strigenz
BCBasil H. Chaballout
Basil H. Chaballout
Anna BlendaAnna Blenda
Anna Blenda
Galectins are proteins with high-affinity β-galactoside-binding sites that function in a variety of signaling pathways through interactions with glycoproteins. The known contributions of galectins-1, -3, -7, -8, and -9 to angiogenesis, metastasis, cell division, and evasion of immune destruction led us to investigate the circulating levels of these galectins in cancer patients. This study compares galectin concentrations by enzyme-linked immunosorbent assay (ELISA) from each stage of breast, lung, and colon cancer. Galectins-1 and -7, which share a prototype structure, were found to have statistically significant increases in breast and lung cancer. Of the tandem-repeat galectins, galectin-8 showed no statistically significant change in these cancer types, but galectin-9 was increased in colon and lung cancer. Galectin-3 is the only chimera-type galectin and was increased in all stages of breast, colon, and lung cancer. In conclusion, there were significant differences in the galectin levels in patients with these cancers compared with healthy controls, and galectin levels did not significantly change from stage to stage. These findings suggest that further research on the roles of galectins early in disease pathogenesis may lead to novel indications for galectin inhibitors.

1 January 2009 in Clinical Colorectal Cancer
Verified
Journal Article
Closed access
JSJoe J. Stephenson
Joe J. Stephenson
CGCharles Gregory
Charles Gregory
HBHoward Burris
Howard Burris
TLTim Larson
Tim Larson
UVUdit Verma
Udit Verma
RARafael G. Amado
Rafael G. Amado

24 August 2011 in Investigational New Drugs
Verified
Journal Article
Closed access
PDF file
RRRamesh K. Ramanathan
Ramesh K. Ramanathan
JSJoe J. Stephenson
Joe J. Stephenson
GWGlen J. Weiss
Glen J. Weiss
LPLinda A. Pestano
Linda A. Pestano
ALAnn Lowe
Ann Lowe
DRDonald A. Richards
Donald A. Richards

1 December 2020 in Respiratory Medicine
Verified
Journal Article
Open access
WGW. Larry Gluck
W. Larry Gluck
SCSean P. Callahan
Sean P. Callahan
RBRobert A. Brevetta
Robert A. Brevetta
ASAntine E. Stenbit
Antine E. Stenbit
WSWesley M. Smith
Wesley M. Smith
WEW. Jeffery Edenfield
W. Jeffery Edenfield
Cytokine release syndrome (CRS) is a potentially severe complication of COVID-19 most commonly resulting in respiratory failure. This ten-patient study was designed to determine the efficacy of therapeutic plasma exchange (TPE) in improving oxygenation and in reducing the cytokine load in a critically ill subset of patients. Five single volume plasma exchanges over eight days within a 14-day study period. In mechanically ventilated patients, oxygenation was measured via the PaO2/FiO2 (P/F) ratio and the oxygenation index (OI) daily for 14 days. Supplemental oxygen requirements were tracked daily for non-ventilated patients. Non-ventilated patients were liberated from supplemental oxygen after TPE. The response was rapid with an 87% average reduction in oxygenation requirements following and average time to return to room air of 5.25 days. All mechanically ventilated patients demonstrated improvement in oxygenation with a 78% average improvement in the P/F ratio and a 43% improvement in OI. C-reactive protein (CRP) and serum levels of IL-6, IL-8, IL-10, TNFα, IFNγ and GM-CSF, were measured daily with immediate post TPE levels drawn on days 1, 2, 4, 6 and 8. All patients demonstrated significant reductions in CRP, IL-6, IL-10 and TNFα. In the majority of patients with Penn class 3 and 4 CRS complicating COVID-19, TPE demonstrated a prompt improvement in oxygenation and reduction in cytokine load without compromising patient safety. As this pilot study was envisioned to be hypothesis generating, expanded trials using TPE alone and in conjunction with novel pharmacologic agents are warranted. ClinicalTrials.gov NCT04374149.